C-VFGBBolden Therapeutics
neurogenesis, antisense oligonucleotides, exon-skipping
modulatingrna therapeutic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-VFGB
C-VFGBC-VFGBneurogenesis, antisense oligonucleotides, exon-skipping
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Bolden Therapeutics neurogenesis, antisense oligonucleotides, exon-skipping
Bolden Therapeutics is developing first-in-class therapeutics to increase neurogenesis, the formation of new brain cells, for neurological disease. The company says it has established proof-of-concept for increasing neurogenesis and enhancing hippocampal-dependent memory in a proprietary mouse model targeting a novel signaling pathway. Bolden is developing multiple therapeutic modalities in parallel, led by exon-skipping antisense oligonucleotides.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Bolden Therapeutics — Early mechanism · Bottom quartile. Derived deterministically from 2 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic